iXCells Biotechnologies

Name

iXCells Biotechnologies

Legal name

iXCells Biotechnologies

Website

https://ixcellsbiotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• IPSC cell products
• Primary cell isolation
• Preclinical CRO services
• CRISPR genome editing
• Cell culture reagents

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cell Products Sales: Sale of iPSC-derived cells, human primary cells, and animal primary cells. Products are cryopreserved and shipped for research use.
2. Cell Media & Reagents: Specialized culture media and reagents for cell growth, differentiation, and maintenance.
3. Preclinical CRO Services: Fee-for-service including iPSC reprogramming, genome editing, differentiation services, custom cell isolation, and assay services.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

iXCells Biotechnologies supplies iPSC-derived cells, primary human and animal cells, and cell culture media/reagents, and provides preclinical CRO services including iPSC reprogramming, CRISPR-based genome editing, directed differentiation, custom cell isolation, high-throughput iPSC production, and disease-specific assay services for drug discovery customers.

Product overview

iXCells Biotechnologies is a preclinical drug discovery company offering a comprehensive portfolio of cell products and CRO services centered on iPSC technology and primary cell models. The product portfolio consists of four main cell product categories (iPSC-derived cells, human primary cells, animal primary cells, and cell media & reagents) complemented by a suite of service offerings. The iPSCore platform serves as the unified platform combining iPSC generation, genome editing, differentiation, and high-throughput screening capabilities. The cell products span neurons (motor, cortical, dopaminergic, sensory, glutamatergic, GABAergic), glial cells (astrocytes, Schwann cells), muscle cells (skeletal myoblasts), and various primary cells from human and animal sources. Services include custom iPSC generation, CRISPR-based genome editing, directed differentiation, custom cell isolation, and high-throughput iPSC production. The company focuses on disease-relevant, patent-derived models for drug discovery and disease understanding, with particular strength in neurological disease models including ALS, Parkinson's, and Alzheimer's.

Differentiator

Problem solved

Functional benefit

Products and services

• iPSC-derived Cells iPSC-derived human cell products including motor neurons, dopaminergic neurons, cortical neurons, sensory neurons, astrocytes, microglia, cardiomyocytes, hepatocytes, and other lineages for disease modeling and drug screening. For pharmaceutical, biotechnology, and academic researchers.
• Human Primary Cells Primary human cells isolated from various tissues and disease backgrounds, supplied as cryopreserved or fresh preparations for research applications. For researchers requiring primary human cellular models.
• Animal Primary Cells Primary animal cells (mouse, rat, and other species) for in vivo-correlative in vitro studies and preclinical research applications. For academic and industry preclinical researchers.
• Cell Media and Reagents Cell culture media, differentiation kits, and reagents formulated to support iPSC maintenance, differentiation, and primary cell culture. For researchers using the company's cell products or running in-house culture workflows.
• iPSC Generation Services Custom iPSC reprogramming from customer-provided somatic cells (PBMCs, fibroblasts, etc.) using non-integrating methods, with characterization and banking. For researchers needing patient- or donor-specific iPSC lines.
• Genome Editing Services CRISPR/Cas9-based gene knockout, knock-in, and point mutation services in iPSCs and primary cells, including clonal expansion and validation. For researchers building isogenic or disease-mutation cell models.
• iPSC Differentiation Services Directed differentiation of customer iPSCs into neurons, cardiomyocytes, hepatocytes, and other lineages using proprietary protocols, with characterization of marker expression and function. For researchers without in-house differentiation capacity.
• Custom Cell Isolation Services Custom isolation of primary cells from customer-provided or procured human or animal tissues using protocol development and cell purification workflows. For researchers requiring rare or specialized primary cell preparations.
• High-Throughput iPSC Production Services Scaled iPSC production and banking under standardized, quality-controlled conditions to support large-cohort or screening-scale programs. For groups running population-scale or screening studies.
• Preclinical CRO Services Integrated preclinical drug discovery services combining disease modeling, target validation, compound screening, and efficacy assessment using iPSC-derived and primary cell platforms. For pharmaceutical and biotech drug discovery programs.
• Assay Services Biological assay services including flow cytometry, immunocytochemistry, qPCR, ELISA, MEA electrophysiology, and patch clamp assays run on customer-supplied or company-provided cell models. For researchers needing outsourced assay execution and readouts.
• Antisense Oligonucleotide (ASO) Screening Services Disease-specific ASO screening services using iPSC-derived neuronal and other disease models, with functional readouts, for neurological and rare disease drug discovery. For antisense therapy developers and rare disease researchers.

Quantifiable outcome

• >85% HB9 positive motor neurons; >90% ISL1 positive cells
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Rosebud BiosciencescoreStrategic or Co-development PartnerInternational collaboration to assess off-target chemotherapeutic toxicity using patient-derived organoids. Combines iXCells' cellular reprogramming expertise with Rosebud's organoid platforms.
• KantifycoreStrategic or Co-development PartnerAI-driven analysis partnership for multi-organ toxicity profiling in oncology research. Enables personalized toxicity profiles using advanced analytics.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• FUJIFILM Cellular Dynamics: Market-leading iPSC-derived cell provider offering neurons, cardiomyocytes, hepatocytes, and other differentiated cell types for drug discovery. Closest direct competitor to iXCells in catalog iPSC-derived neural cells, with substantially greater scale and broader pharma penetration.
• Axol Bioscience: Specialty provider of iPSC-derived human cell types with strong overlap in neural cell products (motor neurons, cortical neurons, astrocytes). Competes with iXCells in the same niche of human iPSC-derived neural models for neuroscience and disease modeling.
• Stemcell Technologies: Broad life science tools company offering primary cells, culture media, and cell isolation products that overlap with iXCells' primary cells and reagents catalog. A major competitor in the cell products and reagents category.
• REPROCELL: iPSC-focused company offering iPSC-derived cell products, reprogramming services, and contract research. Direct competitor to iXCells in iPSC generation services and catalog iPSC-derived neural cells, with comparable specialization in neurological models.
• Ncardia: iPSC-derived cardiac and neuronal cell provider for drug discovery and safety assessment. Competes directly with iXCells' iPSC-derived cardiomyocytes and neural cell lines for pharma preclinical screening applications.
• Cell Applications: Provider of primary human and animal cells, including specialty neural cells, for research applications. Overlaps with iXCells' primary cells catalog across multiple tissue types and species.

Broad incumbents

• Lonza: Global CDMO and cell products provider offering primary cells, media, and cell therapy manufacturing services. Overlaps with iXCells' cell products and CRO services categories but operates at a much larger scale across multiple life science segments.
• Thermo Fisher Scientific: Incumbent life science tools giant offering primary cells, reagents, media, and iPSC-related products through its bioscience brands. Competes with iXCells across the cell products and reagents catalog as part of a much broader portfolio.

Emerging players

• BrainXell: Specialized provider of iPSC-derived neural cells (neurons and glia) for neuroscience research and drug discovery. Closely comparable niche focus on neurological disease models, similar in size and scope to iXCells.
• bit.bio: Synthetic biology company using proprietary cellular reprogramming technology to produce consistent human iPSC-derived cells at scale. Overlaps with iXCells' iPSC reprogramming and differentiation capabilities, with a stronger technology platform differentiation angle.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ixcells
• Facebookfacebook.com/ixcellsbiotech
• LinkedInlinkedin.com/company/ixcells-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iXCells Biotechnologies